scholarly journals NCCN Task Force Report: Bone Health and Cancer Care

2006 ◽  
Vol 4 (S2) ◽  
pp. S-1-S-20 ◽  
Author(s):  
Richard L. Theriault ◽  
J. Sybil Biermann ◽  
Elizabeth Brown ◽  
Adam Brufsky ◽  
Laurence Demers ◽  
...  
Keyword(s):  
Bone Health ◽  
Cancer Care ◽  
Task Force ◽  
Imaging Techniques ◽  
Healthcare Team ◽  
Task Force Report ◽  
Patients With Cancer ◽  
Pathologic Fractures ◽  
Education And Care

Higher incidences of osteoporosis and osteopenia are found in cancer patients, particularly in women receiving aromatase inhibitors or with chemotherapy-induced ovarian failure, or in men with prostate cancer and androgen deprivation therapy. Therefore, management of long-term bone health is emerging as an important aspect of comprehensive cancer care. Patients with cancer typically have a number of additional risk factors for osteoporosis that should prompt screening, regardless of patient age or sex. Maintaining bone health requires a broad knowledge base, including understanding underlying bone metabolism and how it is affected by both cancer itself and the drugs used to treat cancer, the effect of chemotherapy-induced menopause on bone health, bone markers and imaging techniques used to assess bone health, therapeutic strategies to maintain bone health, and treatment of bone metastases, including surgery for pathologic fractures. Multiple members of the healthcare team may need to be involved in education and care of the patient. This report summarizes discussion of these and other issues regarding bone health and cancer care from the NCCN Bone Health and Cancer Care Task Force meeting in early 2006. (JNCCN 2006;4(Suppl 2):S1-S24)

scholarly journals NCCN Task Force Report: Bone Health in Cancer Care

2013 ◽  
Vol 11 (suppl 3) ◽  
pp. S-1-S-50 ◽  
Author(s):  
Julie R. Gralow ◽  
J. Sybil Biermann ◽  
Azeez Farooki ◽  
Monica N. Fornier ◽  
Robert F. Gagel ◽  
...  
Keyword(s):  
Bone Health ◽  
Cancer Care ◽  
Task Force ◽  
Task Force Report

scholarly journals NCCN Task Force Report: Bone Health in Cancer Care

2009 ◽  
Vol 7 (Suppl_3) ◽  
pp. S-1-S-32 ◽  
Author(s):  
Julie R. Gralow ◽  
J. Sybil Biermann ◽  
Azeez Farooki ◽  
Monica N. Fornier ◽  
Robert F. Gagel ◽  
...  
Keyword(s):  
Bone Health ◽  
Cancer Care ◽  
Disease Risk ◽  
Task Force ◽  
Metastatic Cancer ◽  
Cancer Recurrence ◽  
Skeletal Metastases ◽  
Task Force Report ◽  
Skeletal Related Events ◽  
Cancer Network

Bone health and maintenance of bone integrity are important components of comprehensive cancer care in both early and late stages of disease. Risk factors for osteoporosis are increased in patients with cancer, including women with chemotherapy-induced ovarian failure, those treated with aromatase inhibitors for breast cancer, men receiving androgen-deprivation therapy for prostate cancer, and patients undergoing glucocorticoid therapy. The skeleton is a common site of metastatic cancer recurrence, and skeletal-related events are the cause of significant morbidity. The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force on Bone Health in Cancer Care to discuss the progress made in identifying effective screening and therapeutic options for management of treatment-related bone loss; understanding the factors that result in bone metastases; managing skeletal metastases; and evolving strategies to reduce bone recurrences. This report summarizes presentations made at the meeting.

Endocarditis

2016 ◽  
Author(s):  
Gilbert Habib ◽  
Franck Thuny ◽  
Guy Van Camp ◽  
Simon Matskeplishvili
Keyword(s):  
Infective Endocarditis ◽  
Task Force ◽  
Imaging Techniques ◽  
Three Dimensional ◽  
Transoesophageal Echocardiography ◽  
Long Term Prognosis ◽  
Severity Of The Disease ◽  
European Society Of Cardiology ◽  
Embolic Risk

Echocardiography plays a key role in the assessment of infective endocarditis (IE). It is useful both for the diagnosis of endocarditis, the assessment of the severity of the disease, the prediction of short-term and long-term prognosis, the prediction of embolic risk, the management of the complications of endocarditis, and the follow-up of patients under specific antibiotic therapy. The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology and the ‘Recommendations for the practice of echocardiography in infective endocarditis’ of the European Association for Echocardiography have underlined the value and limitations of echocardiography in IE, and gave clear recommendations for the optimal use of both transthoracic and transoesophageal echocardiography in IE. New data in the field of echocardiography in IE includes more extensive use of three-dimensional transoesophageal echocardiography, inclusion of other imaging techniques, and new important publications in the field of the prediction of embolic risk by echocardiography.

scholarly journals Canadian Industrial Relations – The Task Force Report

2005 ◽  
Vol 24 (3) ◽  
pp. 489-497
Author(s):  
Adolf Sturmthal
Keyword(s):  
Task Force ◽  
Full Employment ◽  
Industrial Relations ◽  
Industrial Democracy ◽  
Task Force Report ◽  
Union Security ◽  
Wage Parity

After an overall judgment of the Report, the author examines problems such as the emergency strike, the alienation of the worker, the long-term full employment, inflation, industrial democracy, union certification, union security and wage parity.

Association of fear of COVID-19 with delays in care or treatment interruptions in patients with cancer.

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 98-98
Author(s):  
Karen L. Smith ◽  
Nicole E. Caston ◽  
Valerie Lawhon ◽  
Kathleen D. Gallagher ◽  
Rebekah Angove ◽  
...  
Keyword(s):  
Cancer Care ◽  
Household Income ◽  
Patient Choice ◽  
Cancer Type ◽  
Health Issues ◽  
Time Points ◽  
Patients With Cancer ◽  
Treatment Interruptions ◽  
Time Point

98 Background: Patients with cancer are at risk for severe COVID-19 and may be vulnerable to health care delays. Delays or interruptions in care may lead to adverse cancer outcomes. Little is known about the relationship between fear of COVID-19 and disruptions in cancer care delivery. Methods: This longitudinal survey was distributed to individuals with cancer who received services July 2019-April 2020 from Patient Advocate Foundation, a non-profit organization that provides case management and financial aid to patients with chronic illness. Data was collected twice - early pandemic (5/20/20-7/11/20) and later pandemic (12/3/20-12/23/20). Fear of COVID-19 was assessed with the Fear of COVID-19 Scale and dichotomized as more (≥22) vs less (< 22) fearful. Respondents reported delays in care or treatment interruptions due to the pandemic and reasons for delays or interruptions. Respondents rated concern about potential long-term health issues due to delays on a 5-point Likert-like scale. We estimated predicted percentages and 95% confidence intervals (CI) using logistic regression models to assess the association of fear of COVID-19 (more vs less fearful) with delay in care or treatment interruption (any vs none) at each time point. We adjusted models for age, sex, race/ethnicity, region, annual household income, marital status, employment status, household size, Area Deprivation Index category, Rural-Urban Commuting Code category, county-level COVID-cases per 100,000, cancer type and number of comorbidities. Results: Amongst the 1,199 early pandemic survey respondents, the majority were female (72%), had household income < $48,000 (73%), and had ≥1 comorbidity (60%). 448 of the early pandemic survey respondents also completed the later survey. 464 (39%) and 166 (37%) respondents were categorized as more fearful at the early and later time points respectively. 567 (47%) and 191 (43%) reported delays or interruptions at the early and later time points respectively. The most common reported reasons for delays or interruptions were hospital/provider restrictions (early: 27%, later: 19%) and patient choice (early: 13%, later: 15%). Among respondents with delays or interruptions at each time point, > 70% were at least moderately concerned about potential long-term health issues due to delays. In adjusted models, more fearful respondents had higher predicted percentages of delayed care or treatment interruptions compared to less fearful respondents early (more fearful: 56%, 95% CI 39%-72%; less fearful: 44%; 95% CI 28%-61%) and later (more fearful: 55%, 95% CI 35%-73%; less fearful: 38%; 95% CI 22%-57%) in the pandemic. Conclusions: Fear of COVID-19 is common among patients with cancer and is linked with delays in care and treatment interruptions. System-wide strategies are needed to address fear of COVID-19 and to ensure equitable, timely, and safe access to cancer care throughout the pandemic.

NCCN Bone Health Task Force: Key Recommendations

2014 ◽  
Vol 12 (5S) ◽  
pp. 813-816 ◽  
Author(s):  
Azeez Farooki
Keyword(s):  
Bone Health ◽  
Task Force ◽  
Standard Of Care ◽  
Bisphosphonate Therapy ◽  
Annual Conference ◽  
Estrogen Receptor Modulators ◽  
Antiresorptive Agents ◽  
Safety Considerations ◽  
Receptor Modulators

For patients with advanced cancers involving bone, the standard of care for maintaining bone health is the use of antiresorptive therapies such as bisphosphonates, selective estrogen-receptor modulators, and denosumab. However, although long-term adverse events are rare and the risk-benefit ratio of these agents is usually markedly in favor of treatment, clinicians should be aware that they can occur. At the NCCN 19th Annual Conference, Dr. Azeez Farooki presented the key findings of the NCCN Bone Health Task Force, focusing on such topics as screening for osteoporosis; the controversial use of drug holidays from chronic bisphosphonate therapy; the provocative yet unclear story surrounding the potential anticancer benefits of antiresorptive agents; imaging for metastatic bone disease; and safety considerations linked to calcium supplements, vitamin D, and bone-strengthening agents.

scholarly journals Bisphosphonates and Atypical Fractures of Femur

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Tero Yli-Kyyny
Keyword(s):  
Task Force ◽  
Case Reports ◽  
Term Treatment ◽  
Mineral Research ◽  
Task Force Report ◽  
Treatment Of Osteoporosis ◽  
Atypical Fractures ◽  
Long Term Treatment ◽  
American Society

Bisphosphonates are the most widely prescribed medicines for the treatment of osteoporosis and have generally been regarded as well-tolerated and safe drugs. Since 2005, there have been numerous case reports about atypical fractures of the femur linked to long-term treatment of osteoporosis with bisphosphonates. Some attempts to characterize pathophysiology and epidemiology of these fractures have been published as well. However, as the American Society for Bone and Mineral Research (ASBMR) concluded in their task force report, the subject warrants further studies.

NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer

2009 ◽  
Vol 7 (Suppl_1) ◽  
pp. S-5-S-21 ◽  
Author(s):  
Barbara Burtness ◽  
Milan Anadkat ◽  
Surendra Basti ◽  
Miranda Hughes ◽  
Mario E. Lacouture ◽  
...  
Keyword(s):  
Task Force ◽  
Growth Factor Receptor ◽  
Egfr Inhibitors ◽  
Standards Of Care ◽  
Published Data ◽  
Evidence Based ◽  
Task Force Report ◽  
Egfr Inhibition ◽  
Patients With Cancer ◽  
Epidermal Growth

This NCCN Task Force Report describes the management of dermatologic and ocular toxicities that occur in patients treated with epidermal growth factor receptor (EGFR) inhibitors. Task force members are from NCCN member institutions and include oncologists, dermatologists, an ophthalmologist, and a mid-level oncology provider. This report describes commonly used therapies that the task force agreed are appropriate standards of care for dermatologic and ophthalmologic toxicities associated with EGFR inhibitors, which generally are supported only by anecdotal evidence. Few recommendations are evidence based; however, some commonly used therapies have data supporting their use. Conclusions from completed clinical trials are generally limited by the small numbers of patients enrolled. The information in this report is based on available published data on treating toxicities associated with EGFR inhibitors, data from treatment of clinically similar toxicities from different etiologies, and expert opinion among the NCCN Task Force members.

scholarly journals Electronic cigarettes: a task force report from the European Respiratory Society

2019 ◽  
Vol 53 (2) ◽  
pp. 1801151 ◽  
Author(s):  
Robert Bals ◽  
Jeanette Boyd ◽  
Susanna Esposito ◽  
Robert Foronjy ◽  
Pieter S. Hiemstra ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Health Effects ◽  
Animal Studies ◽  
Social Impact ◽  
Task Force ◽  
Current Knowledge ◽  
Electronic Cigarettes ◽  
Task Force Report ◽  
Behavioural Aspects

There is a marked increase in the development and use of electronic nicotine delivery systems or electronic cigarettes (ECIGs). This statement covers electronic cigarettes (ECIGs), defined as “electrical devices that generate an aerosol from a liquid” and thus excludes devices that contain tobacco. Database searches identified published articles that were used to summarise the current knowledge on the epidemiology of ECIG use; their ingredients and accompanied health effects; second-hand exposure; use of ECIGs for smoking cessation; behavioural aspects of ECIGs and social impact;in vitroand animal studies; and user perspectives.ECIG aerosol contains potentially toxic chemicals. As compared to conventional cigarettes, these are fewer and generally in lower concentrations. Second-hand exposures to ECIG chemicals may represent a potential risk, especially to vulnerable populations. There is not enough scientific evidence to support ECIGs as an aid to smoking cessation due to a lack of controlled trials, including those that compare ECIGs with licenced stop-smoking treatments. So far, there are conflicting data that use of ECIGs results in a renormalisation of smoking behaviour or for the gateway hypothesis. Experiments in cell cultures and animal studies show that ECIGs can have multiple negative effects. The long-term effects of ECIG use are unknown, and there is therefore no evidence that ECIGs are safer than tobacco in the long term. Based on current knowledge, negative health effects cannot be ruled out.

Sign in / Sign up

Export Citation Format

Share Document